Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 897

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 12
Chunk 897
---
3 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, RSUs, PSUs, and other stock-based awards to employees, advisors, consultants and non-employee directors. Following the adoption of the 2023 Plan, we ceased granting equity awards under the 2013 Stock Incentive Plan, or the 2013 Plan. Any outstanding equity awards that were previously granted under the 2013 Plan continue to be governed by their terms. Following adoption of the 2013 Plan, we ceased granting equity awards under the 2007 Stock Incentive Plan, or the 2007 Plan. There are no outstanding equity awards under the 2007 Plan.In connection with the start of employment of our Chief Executive Officer and Chief Financial Officer in 2022, and our Chief Commercial Officer in 2023, our board of directors granted each of them equity awards in the form of stock options, RSUs and PSUs, which awards were made outside our equity incentive plans as inducements material to their respective entry into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).As of December 31, 2024, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 10,896,149, and we had 2,868,747 shares available for future issuance under the 2023 Plan.

F-20

Stock optionsThe following table summarizes the stock option activity of all stock incentive plans for the year ended December 31, 2024:Number ofStockOptionsWeighted-AverageExercisePriceWeighted-AverageRemainingContractualTerm(in years)AggregateIntrinsicValue (inthousands)Outstanding at December 31, 20235,263,681 $44.94 6.36$423 Granted1,050,087 34.40 Exercised(343,341)34.39 Cancelled/Forfeited(79,253)39.00 Expired(56,918)71.76 Outstanding at December 31, 20245,834,256 $43.48 6.21$11,911 Exercisable at December 31, 20243,851,037 $49.62 5.02$6,574 Vested and expected to vest at December 31, 20245,834,256 $